系统性硬化症性别特异性常染色体易感基因位点:全基因组关联研究
该研究对系统性硬化症开展性别分层常染色体GWAS荟萃分析,纳入10 653例患者和18 043例对照。鉴定出8个性别特异性位点,包括1个男性特异性新位点和2个女性特异性新位点,并发现5个基因存在性别差异表达,提示性别感知精准医学潜力。
要点
- IL12RB2等5个基因在患者中显示性别差异表达。
核心结论
- 首次报道系统性硬化症存在性别特异性遗传架构,支持性别感知精准医学。
研究设计与样本
- 基于染色体定义性别,对系统性硬化症GWAS进行性别分层常染色体荟萃分析。
- 纳入10 653例患者(1556例男性、9097例女性)和18 043例对照(6990例男性、11 053例女性)。
主要发现
- 鉴定出8个性别特异性位点:1个男性特异性新位点、2个女性特异性新位点和5个已知女性特异性位点。
- 功能分析提示39个候选基因,其中IL12RB2、ARHGAP31、UBL7、CSK和MPI在患者中显示性别差异表达。
- 药物重定位分析识别fostamatinib和dasatinib为潜在性别感知治疗候选药物。
关键数值与推荐
- 成人患者(≥18岁)需符合2013年ACR-EULAR分类标准或2001年LeRoy和Medsger提出的早期系统性硬化症标准。
临床怎么用
- 研究结果提示IL12RB2基因和干扰素信号通路在系统性硬化症性别差异中的潜在作用。
- fostamatinib和dasatinib被识别为潜在重定位药物,支持开发性别感知精准医学方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic sclerosis is an immune-mediated inflammatory disease with marked sex differences in prevalence and severity. Although genome-wide association studies (GWAS) have advanced the understanding of systemic sclerosis genetics, sex-aware approaches remain scarce. We aimed to address this gap by examining autosomal sex-specific genetic factors in systemic sclerosis. METHODS: Based on a chromosomal definition of sex, we conducted a sex-stratified autosomal meta-analysis of GWAS in systemic sclerosis. We retrieved patient-level and control data from a previous GWAS for systemic sclerosis and newly recruited participants from an international multicentre collaboration (data cutoff June 1, 2024). Adult patients (aged ≥18 years) were required to meet the 2013 American College of Rheumatology-European League Against Rheumatism classification criteria or the criteria for early systemic sclerosis proposed by LeRoy and Medsger, 2001. Patients with systemic sclerosis were compared with healthy controls through sex-stratified analyses. Sex-specific loci were functionally annotated and a sex-differential expression analysis was performed to validate the findings. Additionally, we performed a drug repurposing analysis to explore the clinical implications of our findings. People with lived experience of systemic sclerosis were not involved in the study design or conduct. FINDINGS: After quality control filtering, we included 10 653 patients with systemic sclerosis (1556 male and 9097 female) and 18 043 controls (6990 male and 11 053 female). We identified eight sex-specific loci associated with systemic sclerosis: one novel male-specific locus (BCL11A odds ratio [OR] 1·32 [95% CI 1·20-1·45], p=8·39 × 10-9), two novel female-specific loci (IRF4 OR 0·78 [0·71-0·85], p=2·36 × 10-8RPL3-PDGFB OR 1·19 [1·12-1·26], p=3·18 × 10-8), and five previously known loci now characterised as female-specific. Functional analyses implicated 39 candidate genes, of which five (IL12RB2, ARHGAP31, UBL7, CSK, and MPI) showed sex-differential expression in patients with systemic sclerosis. Two approved drugs, fostamatinib and dasatinib, were identified as potential repurposing candidates for systemic sclerosis sex-aware treatment. INTERPRETATION: We report the first evidence of sex-specific genetic architecture in systemic sclerosis. These findings offer insight into the molecular basis of sex differences in the disease, highlighting both IL12RB2 gene and interferon signalling. These results also support the development of sex-aware precision medicine approaches. FUNDING: Instituto de Salud Carlos III, EU's Seventh Framework Program, and European Federation of Pharmaceutical Industries and Associations companies.
引用
- Rodriguez-Martin I, Kerick M, Rangel-Peláez C, et al. Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study. Lancet Rheumatol. 2026. PMID: 41999721. doi:10.1016/S2665-9913(25)00376-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。